Status:

COMPLETED

Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy Subjects

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Healthy

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

Comparative pharmacokinetics and pharmacodynamics of Asasantin ER at fasted and fed state

Eligibility Criteria

Inclusion

  • Healthy subjects as determined by results of screening
  • Signed written informed consent in accordance with good clinical practice (GCP) and local legislation
  • Age ≥ 18 and ≤ 55 years
  • Broca ≥ - 20 % and ≤ + 20 %

Exclusion

  • Any findings of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastro-intestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
  • Chronic or relevant acute infections
  • History of hypersensitivity to Asasantin ER and any of the excipients
  • Intake of drugs with a long half-life (\> 24 hours) (\< 1 month prior to administration or during the trial)
  • Use of any drugs which might influence the results of the trial (≤ 10 days prior to administration or during the trial)
  • Participation in another trial with an investigational drug (\< 1 month prior to administration or during the trial)
  • Known alcohol abuse
  • Known drug abuse
  • Blood donation (\< 1 month prior to administration)
  • Excessive physical activities (\< 5 days prior to administration)
  • History of hemorrhagic diatheses
  • History of gastro-intestinal ulcer, perforating or bleeding
  • History of bronchial asthma
  • Any laboratory value outside the normal range of clinical relevance
  • Female subjects:
  • Pregnancy
  • Positive pregnancy test
  • No adequate contraception (adequate contraception e.g. sterilization, intrauterine devices (IUD), oral contraceptives)
  • Inability to maintain this adequate contraception during the whole study period
  • Lactation period

Key Trial Info

Start Date :

August 1 1999

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT02273492

Start Date

August 1 1999

Last Update

October 24 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.